

ASX RELEASE

New Zealand Breast Screening First to Utilize Volpara AI Software to Improve Mammography Quality

BreastScreen Central Utilizes VolparaEnterprise™ Software to Deliver High-Quality Screening

Athens, Greece, 12th October 2018: [Volpara Health Technologies](#) ("Volpara"; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, will be announcing shortly at the European Society of Breast Imaging Annual Scientific Meeting the first public screening sector purchase of its **VolparaEnterprise™** software. BreastScreen Central, a lead provider for BreastScreen New Zealand, has purchased the analytics software to help deliver high-quality, breast cancer screening to women living in the Wellington region.

Volpara is in multiple large-scale trials with public screening programs across Europe and APAC of its Enterprise software, including the PROCAS II project with the National Health Service in the UK, one of the world's largest screening programs. BreastScreen Central is the first such organization in the world to purchase the VolparaEnterprise software to use as a key component of its quality assurance protocols, monitoring breast compression, positioning and other factors to improve the consistency of mammographic imaging and patient experience.

"Having access to a tool that analyses our mammograms is helping us to maintain and to continually seek to improve our image quality and the overall experience of our clients," said Hayley Shatford, Lead Technologist, BreastScreen Central. "It has been invaluable in supporting the training of new staff, as image quality is vital in increasing cancer detection rates,"

VolparaEnterprise software delivers key performance indicators for over 100 performance and quality metrics, including patient positioning and compression, which are widely viewed as the causes of most clinical image deficiencies, and associated with delayed detection of breast cancer. VolparaEnterprise software enables users to perform rapid quality control checks that help optimize the productivity and efficiency of imaging resources. This in turn helps decrease costs through the reduction of retakes, increase employee effectiveness, and enhance the patient experience.

"The BreastScreen New Zealand programme is performing extremely important work to improve access to and compliance with breast cancer screening in New Zealand" said Paul Clancy, Volpara's Asia-Pacific Regional Manager. "We are honoured to work with them to incorporate Volpara's mammographic quality tools into the screening programme to help maintain accurate and consistent screening for all women."

ENDS.

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
t: +61 3 9866 4722

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose and quality, while its enterprise-wide software, VolparaEnterprise, provides role specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.

VHT's technology and services have been used by customers and/or research projects in 36 countries and are supported by numerous patents, trademarks and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$40 million, including A\$20 million in April and May 2018. VHT is based in Wellington, New Zealand.

For more information, visit www.volparasolutions.com.